Lebrikizumab delivered long-term disease control for up to four years in patients with moderate-to-severe atopic dermatitis
Go back to Lebrikizumab delivered long-term disease control for up to four years in patients with moderate-to-severe atopic dermatitis| Alabama Power Co. 5.875% Sr. Notes Series 2007B (NASDAQ: ALM) | Delayed: 18.46 -0.2 (1.07%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $18.66 | 52 Week High | $27.10 | |||
| Open | $17.50 | 52 Week Low | $24.10 | |||
| Day High | $18.59 | P/E | N/A | |||
| Day Low | $17.10 | EPS | $0.00 | |||
| Volume | 1,454,595 | |||||
| Alabama Power Co. 5.875% Sr. Notes Series 2007B (NASDAQ: ALM) | Delayed: 18.46 -0.2 (1.07%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $18.66 | 52 Week High | $27.10 | |||
| Open | $17.50 | 52 Week Low | $24.10 | |||
| Day High | $18.59 | P/E | N/A | |||
| Day Low | $17.10 | EPS | $0.00 | |||
| Volume | 1,454,595 | |||||
